Phase 1 (qualifier value)
AbbVie Acquires Rights to Ichnos Glenmark’s Lead Myeloma Antibody (ISB 2001) in $1.93 Billion Deal
AbbVie; Ichnos Glenmark; ISB 2001; trispecific antibody; multiple myeloma; biotech deal; CD3; BCMA; CD38; Phase 1 clinical trial; global licensing; oncology
Metsera Reports Once-Monthly Amylin Analogue Matches GLP-1 Efficacy in Early Phase 1 Results
Metsera; MET-233i; amylin; obesity; weight-loss; GLP-1; once-monthly; clinical trial; phase 1
Kymera Soars on Early Protein Degrader Data
Kymera Therapeutics; KT-621; STAT6 degrader; protein degradation; Phase 1 clinical trial; autoimmune disease
Vigil Neuroscience’s Oral Alzheimer’s Candidate VG-3927 Shows Promising Phase 1 Results with Sanofi’s Strategic Support
Vigil Neuroscience, VG-3927, Alzheimer’s disease, Phase 1 clinical trial, Sanofi strategic investment, TREM2 agonist program, Microglia therapy
Centessa’s ORX750 Demonstrates Promising ‘Best-in-Class’ Profile in Early Narcolepsy Trial
Centessa Pharmaceuticals, ORX750, narcolepsy, orexin receptor 2 agonist, sleep-wake disorders, clinical trial, Phase 1 data
Nuvation Bio Halts Development of BET Inhibitor NUV-868 Following Interim Phase 1 Data Review
Nuvation Bio, BET inhibitor, NUV-868, Phase 1 data, oncology drug, safety and efficacy, clinical trials
Amgen Discontinues Obesity Program, Shifts Focus to MariTide after Phase 1 Results
Amgen, obesity asset, phase 1 results, MariTide, drug development, biotechnology, clinical trials